- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03168776
PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients With Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary stents.
This prospective, global, multi-center, randomized 2:1, single blind study will enroll up to 1632 subjects at up to 130 investigational sites in North America, Japan, and Europe. Subjects will have clinical follow-up in-hospital and at 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bonheiden, Belgium, 2820
- Imelda
-
Charleroi, Belgium
- Chu Charleroi
-
Genk, Belgium, 3600
- Ziekenhuis Oost Limburg Genk
-
Hasselt, Belgium, 3500
- Jessa hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N-2T9
- Foothills Medical Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5B-1W8
- St. Michael's Hospital
-
-
-
-
Kamakura City
-
Kanagawa, Kamakura City, Japan, 247-8533
- Shonan Kamakura General Hospital
-
-
-
-
-
Amsterdam, Netherlands
- Amsterdam UMC
-
Leeuwarden, Netherlands
- MCL
-
Rotterdam, Netherlands
- Maasstad Ziekenhuis
-
-
-
-
-
Barcelona, Spain
- Hospital Clínic de Barcelona
-
Barcelona, Spain
- Hospital Universitari de Bellvitge
-
Madrid, Spain
- Hospital Ramon y Cajal
-
Madrid, Spain
- Instituto de Investigación Hospital 12 de Octubre
-
Vigo, Spain, 36312
- Hospital Álvaro Cunqueiro
-
-
-
-
-
Bern, Switzerland, 3010
- Inselspital, Universitätsspital Bern
-
Geneva, Switzerland, 1211
- University Hospital Geneva HUG, Clinic for Cardiology
-
-
-
-
-
London, United Kingdom
- St Bartholomew'S Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35211
- Cardiology, PC
-
-
Arizona
-
Gilbert, Arizona, United States, 85297
- Dignity Health - Mercy Gilbert Medical Center / Chandler Regional Medical Center
-
-
California
-
Los Angeles, California, United States, 90048
- Smidt Heart Institute Cedars-Sinai Maedical Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Medstar Washington HWospital Center
-
-
Florida
-
Boynton Beach, Florida, United States, 33435
- Bethesda Hospital East/Daniel Heart and Vascular Center
-
Clearwater, Florida, United States, 33756
- Clearwater Cardiovascular Consultants
-
Ocala, Florida, United States, 34471
- Mediquest Research Group Inc.
-
Panama City, Florida, United States, 32401
- Cardiovascular Institute of Northwest Florida
-
Tampa, Florida, United States, 33613
- Florida Hospital Tampa
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Krannert Institute of Cardiology
-
Indianapolis, Indiana, United States, 46290
- St. Vincent's Medical Group
-
-
Iowa
-
Des Moines, Iowa, United States, 50314
- Iowa Heart Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40241
- Norton Brownsboro Hospital
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- MedStar Union Memorial Hospital
-
-
Michigan
-
Petoskey, Michigan, United States, 49770
- Northern Michigan Hospital d.b.a. McLaren Northern Michigan
-
Royal Oak, Michigan, United States, 48073
- William Beaumont Hospital
-
Ypsilanti, Michigan, United States, 48197
- Michigan Heart
-
-
Minnesota
-
Duluth, Minnesota, United States, 55805
- Essential Health
-
-
Mississippi
-
Tupelo, Mississippi, United States, 38801
- North MS Medical Center
-
-
Nebraska
-
Omaha, Nebraska, United States, 68124
- CHI Health Research Center
-
-
New Jersey
-
Haddon Heights, New Jersey, United States, 08035
- Cardiovascular Associates of Delaware Valley
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center / New York Presbyterian Hospital
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- NC Heart and Vascular Research
-
-
Ohio
-
Canton, Ohio, United States, 44710
- Aultman Hospital
-
Cincinnati, Ohio, United States, 45219
- Lindner Research Center
-
Elyria, Ohio, United States, 44035
- North Ohio Heart
-
Kettering, Ohio, United States, 45429
- Kettering Medical Center
-
Toledo, Ohio, United States, 43608
- Mercy St. Vincent Medical Center
-
Zanesville, Ohio, United States, 43701
- Genesis Hospital
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17822
- Geisinger Clinic
-
Doylestown, Pennsylvania, United States, 18901
- Doylestown Hospital
-
Wyomissing, Pennsylvania, United States, 19610
- Berks Cardiologists, Ltd.
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Anderson, South Carolina, United States, 29621
- AnMed Health
-
-
Texas
-
Tyler, Texas, United States, 75701
- Tyler Cardiovascular Consultants
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health System
-
Winchester, Virginia, United States, 22601
- Winchester Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98122
- Swedish Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient is a male or non-pregnant female ≥20 years of age.
- The patient has symptomatic ischemic heart disease, including chronic stable angina (and/or objective evidence of myocardial ischemia on functional study or invasive fractional flow reserve [FFR] measurement) or acute coronary syndromes (UA or NSTEMI), that requires elective or urgent percutaneous coronary intervention (PCI).
- The patient is an acceptable candidate for percutaneous coronary intervention (PCI) with drug-eluting stents, and for emergent coronary bypass graft (CABG) surgery.
- The patient is willing to comply with specified follow-up evaluations.
- The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).
Exclusion Criteria:
- Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of childbearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test.
- Patients with a history of bleeding diathesis or coagulopathy, contraindications to anti-platelet and/or anticoagulant therapy, or who will refuse transfusion.
- Patients who are receiving or will require chronic anticoagulation therapy for any reason.
- Known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, ADP receptor antagonists (clopidogrel, prasugrel, ticagrelor, ticlopidine), cobalt chromium, 316L stainless steel or platinum, sirolimus or its analogues, and/or contrast sensitivity that cannot be adequately pre-medicated.
- ST-segment elevation myocardial infarction (STEMI) at index presentation or within 7 days prior to randomization.
- Known LVEF <30% or cardiogenic shock requiring pressors or mechanical circulatory assistance (e.g., intra-aortic balloon pump, left ventricular assist device, other temporary cardiac support blood pump).
- Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation or Cockcroft-Gault formula) or dialysis at the time of screening.
- Target vessel percutaneous coronary intervention with stent placement in the previous 3 months.
- Planned elective surgery that would require discontinuation of DAPT within 6 months of the index procedure.
- Past or pending heart or any other organ transplant, or on the waiting list for any organ transplant.
- Patients who are receiving immunosuppressant therapy, or who have known immunosuppressive or severe autoimmune disease that will require chronic immunosuppressive therapy. NOTE: Corticosteroid use is permitted.
- Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound data interpretation, or is associated with a life expectancy of less than 1 year.
- Current participation in another investigational drug or device study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: BuMA Supreme Coronary Stent System
|
Implant BuMA Supreme stent only
|
ACTIVE_COMPARATOR: Xience or Promus Everolimus Stent System
|
Implant XIENCE family or Promus family only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target lesion failure (TLF)
Time Frame: 12 months
|
defined as the composite of cardiac death, target vessel related myocardial infarction (TV-MI), and clinically-driven target lesion revascularization (TLR)
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-term Safety and Efficacy defined as target lesion failure (TLF) between 12 months and 5 years by landmark analysis
Time Frame: Between 12 months and 5 years
|
TLF is defined as the composite of cardiac death, target vessel related myocardial infarction (TV-MI), and clinically-driven target lesion revascularization (TLR)
|
Between 12 months and 5 years
|
Major adverse cardiac events (MACE)
Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
defined as a composite of all-cause death, myocardial infarction, and target vessel revascularization
|
30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
Mortality
Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
classified as cardiac or non-cardiac, and reported cumulatively and individually
|
30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
Myocardial infarction (MI)
Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
defined according to the modified Third Universal Definition
|
30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
Stent thrombosis
Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
definite or probable (ARC-defined), classified as early, late, or very late
|
30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
Bleeding complications (BARC definitions)
Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
evaluated as components and as a composite of BARC Type 3 and 5 bleeding
|
30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
Lesion success
Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
defined as attainment of <30% residual stenosis, as measured by quantitative coronary angiography (QCA) using any percutaneous method [evaluated post-procedure]
|
30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
Device success
Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
defined as attainment of <30% residual stenosis of the target lesion measured by QCA using the assigned device [evaluated post-procedure]
|
30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
Procedure success
Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
defined as lesion success without the occurrence of in-hospital MACE [evaluated in-hospital]
|
30 days, 6 months, 12 months, and 2, 3, 4, and 5 years
|
Clinically-driven target lesion revascularization (TLR)
Time Frame: 30 days, 6 months, and 1, 2, 3, 4, and 5 years
|
[evaluated in hospital and at 30 days, 6 months, and 1, 2, 3, 4 and 5 years]
|
30 days, 6 months, and 1, 2, 3, 4, and 5 years
|
Clinically-driven target vessel revascularization (TVR)
Time Frame: 30 days, 6 months, and 1, 2, 3, 4, and 5 years
|
[evaluated in hospital and at 30 days, 6 months, and 1, 2, 3, 4 and 5 years]
|
30 days, 6 months, and 1, 2, 3, 4, and 5 years
|
Target vessel failure (TVF)
Time Frame: 30 days, 6 months, and 1, 2, 3, 4, and 5 years
|
defined as cardiac death, target vessel-related MI, or clinically-driven target vessel revascularization [evaluated in hospital and at 30 days, 6 months, and 1, 2, 3, 4 and 5 years]
|
30 days, 6 months, and 1, 2, 3, 4, and 5 years
|
Target Lesion Failure (TLF)
Time Frame: 30 days, 6 months, and 2, 3, 4, and 5 years
|
defined as cardiac death, target vessel-related MI, or clinically-driven target lesion revascularization [evaluated in hospital and at 30 days, 6 months, and 2, 3, 4 and 5 years]
|
30 days, 6 months, and 2, 3, 4, and 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Martin B Leon, MD, Center for Interventional Vascular Therapy - Columbia University Medical Center / New York-Presbyterian Hospital, United States
- Principal Investigator: Dean Kereiakes, MD, The Christ Hospital Physicians - Ohio Heart & Vascular, United States
- Principal Investigator: Stephan Windecker, MD, Bern University Hospital Department for Cardiology, Switzerland
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIN-US-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on BuMA Supreme DES
-
Sino Medical Sciences Technology Inc.Active, not recruitingCoronary Artery DiseaseChina
-
Sino Medical Sciences Technology Inc.CompletedCoronary Artery Disease | Stable Angina Pectoris | Unstable Angina PectorisChina
-
Sino Medical Sciences Technology Inc.Active, not recruitingCoronary Artery DiseaseChina
-
Sino Medical Sciences Technology Inc.CompletedCoronary Artery DiseaseNetherlands, Belgium, Spain, Portugal
-
Schulthess KlinikUniversity of SalzburgCompletedAdverse Anesthesia Outcome
-
Sino Medical Sciences Technology Inc.CompletedCoronary Heart Disease | Stable Angina Pectoris | Unstable Angina Pectoris | Silent Myocardial IschemiaChina
-
Fondazione Evidence per Attività e Ricerche Cardiovascolari...Mediolanum Cardio ResearchCompletedMyocardial Infarction
-
Kocaeli UniversityUnknownIntra Ocular PressureTurkey
-
Boston Scientific CorporationLabcoat, Ltd.Completed